Testing Our Limits, Episode 2: The Path Forward

It’s soon apparent that meeting daily won’t cut it. The work needs to happen ‘round the clock, 24/7. And even with that dedication from peoples with decades of experience, they’re going to some good luck to break their way too, particularly when it came to acquiring the samples needed to design a test that could identify COVID-19.

“Getting samples that we could use to develop the molecular test was really challenging, mostly because there just weren’t very many cases in the United States and we weren’t able to bring in samples from other parts of the world,” said Mary Rodgers, principal scientist for infectious disease research, Abbott Diagnostics.

Added Gavin Cloherty, head of infectious disease research, Abbott Diagnostics: “Once the first sequence became publicly available, we had a team in place, and as soon as we had that, we literally built a test from a single sequence.”

Learn more about how Abbott’s diagnostics are helping to slow the COVID-19 pandemic: https://abbo.tt/37ht6os

Subscribe to the Abbott Channel and receive automatic updates: https://www.youtube.com/channel/UC346EX3v26ACsjLhe-HwHDg/?sub_confirmation=1

Find out more about us and our products on http://www.abbott.com/

Connect with us on ...
Facebook: https://www.facebook.com/Abbott/
Twitter: https://twitter.com/abbottnews
Instagram: https://www.instagram.com/abbottglobal/
LinkedIn: https://www.linkedin.com/company/abbott-/
YouTube: https://www.youtube.com/channel/UC346EX3v26ACsjLhe-HwHDg/featured